Cited by 214Alzheimer's disease research and treatmentsDown syndrome and intellectual disability researchDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.

Early Amyloid Deposition in the Medial Temporal Lobe of Young Down Syndrome Patients: A Regional Quantitative Analysis

Leverenz, James B., Raskind, Murray A.·1998·Experimental Neurology

DOI 10.1006/exnr.1997.6777

Open this paper in CoChat — free account

Abstract

The presence of the neuropathological alterations of Alzheimer's disease (AD) in essentially all older Down syndrome (DS) patients suggests that the examination of younger DS patients may clarify the early pathological progression of AD. We examined the hippocampus and parahippocampal-inferior temporal gyri of 42 DS patients (ages 4 days to 38 years) for the deposition of amyloid beta protein (Abeta) using both a modified Bielschowsky stain and immunohistochemistry for Abeta protein. The parahippocampal and inferior temporal gyri demonstrated Abeta staining in cases as young as 8 years of age. As age and degree of Abeta deposition increased, staining included the CA-1/subiculum and dentate molecular layer followed then by the remainder of the CA hippocampal regions. The first neuritic plaques were observed in the CA-1/subiculum, despite this being a later region of Abeta deposition. Although Abeta staining increased with age, there was substantial variability in the severity of Abeta deposition within age groups. These results suggest that within the hippocampal/parahippocampal region there is a progressive stereotypic deposition of Abeta. The variable severity of Abeta deposition within age groups suggests that other factors, besides DS, may be contributing to the timing and severity of Abeta deposition.

Integrity signals

Registry

Crossref · 10.1006/exnr.1997.6777

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Untitled work
(1968) · Medical Entomology and Zoology · Cited by 4,924
Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease
Gómez-Isla, T., Price, J. L., McKeel Jr., D. W., Morris, J. C., Growdon, J. H., & Hyman, B. T. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-14-04491.1996 · Cited by 1,796
The human nervous system
Paxinos, G., & Jürgen, K. (2004) · Cited by 1,478
Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome
Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170310 · Cited by 1,159
The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease
Price, J. L., Davis, P. B., Morris, J. C., & White, D. L. (1991) · Neurobiology of Aging · doi:10.1016/0197-4580(91)90006-6 · Cited by 818
Amyloid A4 Protein and Its Precursor in Down's Syndrome and Alzheimer's Disease
Rumble, B. A., Retallack, R. W., Hilbich, C., Simms, G., Multhaup, G., Martins, R. N., Hockey, A., Montgomery, P., Beyreuther, K. T., & Masters, C. L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906013202203 · Cited by 656
Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer’s disease
Arriagada, P. V., Marzloff, K., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.9.1681 · Cited by 638
Sequence of Deposition of Heterogeneous Amyloid β-Peptides and APO E in Down Syndrome: Implications for Initial Events in Amyloid Plaque Formation
Lemere, C. A., Blusztajn, J. K., Yamaguchi, H., Wisniewski, T., Saido, T. C., & Selkoe, D. J. (1996) · Neurobiology of Disease · doi:10.1006/nbdi.1996.0003 · Cited by 584
Amyloid β-protein deposition in tissues other than brain in Alzheimer's disease
Joachim, C. L., Mori, H., & Selkoe, D. J. (1989) · Nature · doi:10.1038/341226a0 · Cited by 462

Flagged first, then by citations

Show all 33 references

1 of the 33 references couldn’t be matched to a known paper.

Research works printed but not linked: 3

Bertrand, 1946, Cas d'idiotic mongolienne adulte avec nombreuses plaques seniles et concretions calcaires pallidales, Rev. Neurol. (Paris), 78, 338
Royston, 1994, Quantitative analysis of β-amyloid deposition in Down's syndrome using computerized image analysis, Neurodegeneration, 3, 43
Ter-Minassian, 1992, Beta amyloid protein immunoreactive senile plaques in infantile Down's syndrome, Soc. Neurosci. Abstr., 18, 734

Sorted by citations

Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194
A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome
Wiseman, F. K., Al-Janabi, T., Hardy, J., Karmiloff-Smith, A., Nizetic, D., Tybulewicz, V. L. J., Fisher, E. M. C., & Strydom, A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3983 · Cited by 562
Cognitive deficits and associated neurological complications in individuals with Down's syndrome
Lott, I. T., & Dierssen, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70112-5 · Cited by 484
Alzheimer’s disease: insights into pathology, molecular mechanisms, and therapy
Zheng, Q., & Wang, X. (2024) · Protein & Cell · doi:10.1093/procel/pwae026 · Cited by 483
Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer’s disease
D'Andrea, M. R., Nagele, R. G., Wang, H., Peterson, P. A., & Lee, D. H. S. (2001) · Histopathology · doi:10.1046/j.1365-2559.2001.01082.x · Cited by 390
Dementia in Down syndrome: unique insights for Alzheimer disease research
Lott, I. T., & Head, E. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0132-6 · Cited by 383
Sequence of Aβ-protein deposition in the human medial temporal lobe
Thal, D. R., Rüb, U., Schultz, C., Sassin, I., Ghebremedhin, E., Del Tredici, K., Braak, E., & Braak, H. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.8.733 · Cited by 370
Alzheimer's disease associated with Down syndrome: a genetic form of dementia
Fortea, J., Zaman, S. H., Hartley, S., Rafii, M. S., Head, E., & Carmona-Iragui, M. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00245-3 · Cited by 357
Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology
Head, E., T. Lott, I., M. Wilcock, D., & A. Lemere, C. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666151020114607 · Cited by 289
Oxidative damage in neurodegeneration: roles in the pathogenesis and progression of Alzheimer disease
Marzia Perluigi, A., Domenico, F. D., & Butterfield, D. A. (2023) · Physiological Reviews · doi:10.1152/physrev.00030.2022 · Cited by 322
Brain, aging and neurodegeneration: Role of zinc ion availability
Mocchegiani, E., Bertoni–Freddari, C., Marcellini, F., & Malavolta, M. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.04.005 · Cited by 281
Alzheimer's disease in Down syndrome: Neurobiology and risk
Zigman, W. B., & Lott, I. T. (2007) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.20163 · Cited by 290
Human astrocytes in the diseased brain
Dossi, E., Vasile, F., & Rouach, N. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.02.001 · Cited by 250
Time Course of the Development of Alzheimer-like Pathology in the Doubly Transgenic PS1+APP Mouse
Gordon, M. N., Holcomb, L. A., Jantzen, P. T., DiCarlo, G., Wilcock, D., Boyett, K. W., Connor, K., Melachrino, J., O'Callaghan, J. P., & Morgan, D. (2002) · Experimental Neurology · doi:10.1006/exnr.2001.7754 · Cited by 247
The genetics and neuropathology of Alzheimer’s disease
Schellenberg, G. D., & Montine, T. J. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0996-2 · Cited by 256
The Development of Amyloid β Protein Deposits in the Aged Brain
Thal, D. R., Capetillo-Zarate, E., Del Tredici, K., & Braak, H. (2006) · Science of Aging Knowledge Environment · doi:10.1126/sageke.2006.6.re1 · Cited by 234
Neuropathology of Alzheimer’s disease: a critical update
Jellinger, K. A., & Bancher, C. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-7508-8_8 · Cited by 233
Down’s syndrome, neuroinflammation, and Alzheimer neuropathogenesis
Wilcock, D. M., & Griffin, W. S. T. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-84 · Cited by 230
Neurological phenotypes for Down syndrome across the life span
Lott, I. T. (2012) · Progress in Brain Research · doi:10.1016/b978-0-444-54299-1.00006-6 · Cited by 225
“The parahippocampal and inferior temporal gyri demonstrate b-amyloid staining as young as 8years of age with subsequent accumulation in the CA-1/subiculum, dentate molecular layer, and the remainder of the hippocampal area (Leverenz and Raskind, 1998).”
Background
Alzheimer disease and Down syndrome: factors in pathogenesis
Lott, I. T., & Head, E. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.08.005 · Cited by 212
The importance of understanding individual differences in Down syndrome
Karmiloff‐Smith, A., Al‐Janabi, T., D’Souza, H., Groet, J., Massand, E., Mok, K. Y., Startin, C. M., Fisher, E., Hardy, J., Nižetić, D., et al. (2016) · F1000Research · doi:10.12688/f1000research.7506.1 · Cited by 214
Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia
Ferrer, I. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.03.005 · Cited by 174
Acute Injections of the NMDA Receptor Antagonist Memantine Rescue Performance Deficits of the Ts65Dn Mouse Model of Down Syndrome on a Fear Conditioning Test
Costa, A. C. S., Scott-McKean, J. J., & Stasko, M. R. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301535 · Cited by 167
Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain
Perluigi, M., Pupo, G., Tramutola, A., Cini, C., Coccia, R., Barone, E., Head, E., Butterfield, D. A., & Di Domenico, F. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.04.007 · Cited by 155
Dysfunction of autophagy and endosomal-lysosomal pathways: Roles in pathogenesis of Down syndrome and Alzheimer’s Disease
Colacurcio, D. J., Pensalfini, A., Jiang, Y., & Nixon, R. A. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.10.001 · Cited by 167
Down syndrome and Alzheimer's disease: A link between development and aging
Lott, I. T., & Head, E. (2001) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.1025 · Cited by 161
The age of onset and evolution of Braak tangle stage and Thal amyloid pathology of Alzheimer’s disease in individuals with Down syndrome
Davidson, Y. S., Robinson, A., Prasher, V. P., & Mann, D. M. A. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0559-4 · Cited by 146
Trisomy of human chromosome 21 enhances amyloid-β deposition independently of an extra copy of APP
Wiseman, F. K., Pulford, L. J., Barkus, C., Liao, F., Portelius, E., Webb, R., Chávez-Gutiérrez, L., Cleverley, K., Noy, S., Sheppard, O., et al. (2018) · Brain · doi:10.1093/brain/awy159 · Cited by 133
Alzheimer's Disease Amyloid-β Links Lens and Brain Pathology in Down Syndrome
Moncaster, J. A., Pineda, R., Moir, R. D., Lu, S., Burton, M. A., Ghosh, J. G., Ericsson, M., Soscia, S. J., Mocofanescu, A., Folkerth, R. D., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010659 · Cited by 142
The GABAergic Hypothesis for Cognitive Disabilities in Down Syndrome
Contestabile, A., Magara, S., & Cancedda, L. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00054 · Cited by 141
Oxidative stress: A bridge between Down's syndrome and Alzheimer's disease
Zana, M., Janka, Z., & Kalman, J. L. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.008 · Cited by 140
Untitled work
(2012) · PubMed
Nerve growth factor metabolic dysfunction in Alzheimer's disease and Down syndrome
Iulita, M. F., & Cuello, A. C. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.04.010 · Cited by 141
Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain
Nistor, M., Don, M., Parekh, M., Sarsoza, F. M., Goodus, M. T., López, G., Kawas, C. H., Leverenz, J. B., Doran, E. W., Lott, I. T., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.06.023 · Cited by 137
Self-citation
Communication breaks-Down: From neurodevelopment defects to cognitive disabilities in Down syndrome
Contestabile, A., Benfenati, F., & Gasparini, L. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.01.003 · Cited by 134
Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: Redox proteomics analysis of human brain
Domenico, F. D., Coccia, R., Cocciolo, A., Murphy, M. P., Cenini, G., Head, E., Butterfield, D. A., Giorgi, A., Schininà, M. E., Mancuso, C., et al. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.04.013 · Cited by 132
Secretase Targets for Alzheimer's Disease: Identification and Therapeutic Potential
Wolfe, M. S. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0004897 · Cited by 135
FAD mutant PS-1 gene-targeted mice: increased Aβ42 and Aβ deposition without APP overproduction
Flood, D. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00330-x · Cited by 131
Maturation of the hippocampal formation and amygdala in Macaca mulatta: A volumetric magnetic resonance imaging study
Payne, C., Machado, C. J., Bliwise, N. G., & Bachevalier, J. (2010) · Hippocampus · doi:10.1002/hipo.20688 · Cited by 129
“…behavioral abnormalities consistent with malfunctions of the hippocampal formation and/or the amygdala (Uecker et al., 1993; Dierssen et al., 1996; Raymond et al., 1996; Leverenz and Raskind, 1998; Harrison, 1999; Saitoh et al., 2001; Machado and Bachevalier, 2003; Bauman and Kemper, 1985, 2005).”
Background
Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome
Cenini, G., Dowling, A. L. S., Beckett, T. L., Barone, E., Mancuso, C., Murphy, M. P., LeVine, H., Lott, I. T., Schmitt, F. A., Butterfield, D. A., et al. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.10.001 · Cited by 126
The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome
Węgiel, J., Dowjat, K., Kaczmarski, W., Kuchna, I., Nowicki, K., Frackowiak, J., Mazur‐Kolecka, B., Wegiel, J., Silverman, W. P., Reisberg, ‌., et al. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0419-6 · Cited by 113
Down syndrome individuals with Alzheimer's disease have a distinct neuroinflammatory phenotype compared to sporadic Alzheimer's disease
Wilcock, D. M., Hurban, J., Helman, A. M., Sudduth, T. L., McCarty, K. L., Beckett, T. L., Ferrell, J. C., Murphy, M. P., Abner, E. L., Schmitt, F. A., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.05.016 · Cited by 110
Down Syndrome: Advances in Molecular Biology and the Neurosciences
Capone, G. T. (2001) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/00004703-200102000-00007 · Cited by 110
Amyloid β-Exposed Human Astrocytes Overproduce Phospho-Tau and Overrelease It within Exosomes, Effects Suppressed by Calcilytic NPS 2143—Further Implications for Alzheimer's Therapy
Chiarini, A., Armato, U., Gardenal, E., Gui, L., & Prà, I. D. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00217 · Cited by 109
Neuroinflammation in the Aging Down Syndrome Brain; Lessons from Alzheimer's Disease
Wilcock, D. M. (2012) · Current Gerontology and Geriatrics Research · doi:10.1155/2012/170276 · Cited by 104
Estrogen restores cognition and cholinergic phenotype in an animal model of Down syndrome
Granholm, A., Ford, K. A., Hyde, L. A., Bimonte, H. A., Hunter, C. L., NELSON, M., Albeck, D. S., Sanders, L., Mufson, E. J., & Crnic, L. S. (2002) · Physiology & Behavior · doi:10.1016/s0031-9384(02)00884-3 · Cited by 104
Spatial Vision Deficits in Infants and Children with Down Syndrome
John, F. M. (2004) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.03-0951 · Cited by 104
Complement Association with Neurons and β-Amyloid Deposition in the Brains of Aged Individuals with Down Syndrome
Head, E., Azizeh, B. Y., Lott, I. T., Tenner, A. J., Cotman, C. W., & Cribbs, D. H. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0380 · Cited by 103
Chapter 4 Alzheimer's Disease in Adults with Down Syndrome
Zigman, W. B., Devenny, D. A., Krinsky‐McHale, S. J., Jenkins, E. C., Urv, T. K., Węgiel, J., Schupf, N., & Silverman, W. P. (2008) · International review of research in mental retardation · doi:10.1016/s0074-7750(08)00004-9 · Cited by 106
Normalizing the gene dosage of Dyrk1A in a mouse model of down syndrome rescues several Alzheimer’s disease phenotypes
García-Cerro, S., Rueda, N., Vidal, V., Lantigua, S., & Martínez-Cué, C. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.06.010 · Cited by 100
The impact of sleep disruption on executive function in Down syndrome
Chen, C., Spanò, G., & Edgin, J. O. (2013) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2013.03.009 · Cited by 98
Link Between DYRK1A Overexpression and Several-Fold Enhancement of Neurofibrillary Degeneration With 3-Repeat Tau Protein in Down Syndrome
Węgiel, J., Kaczmarski, W., Barua, M., Kuchna, I., Nowicki, K., Wang, K.-C., Wegiel, J., Mazur‐Kolecka, B., Frackowiak, J., Mazur‐Kolecka, B., et al. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318202bfa1 · Cited by 98
Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease
Domenico, F. D., Pupo, G., Tramutola, A., Giorgi, A., Schininà, M. E., Coccia, R., Head, E., Butterfield, D. A., & Marzia Perluigi, A. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.03.027 · Cited by 98
Effects of Chronic Glucocorticoid Administration on Insulin-Degrading Enzyme and Amyloid-Beta Peptide in the Aged Macaque
Kulstad, J. J., McMillan, P. J., Leverenz, J. B., Cook, D. G., Green, P. S., Peskind, E. R., Wilkinson, C. W., Farris, W., Mehta, P. D., & Craft, S. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.2.139 · Cited by 96
Self-citation
Characterization of Aβ11-40/42 peptide deposition in Alzheimer’s disease and young Down’s syndrome brains: implication of N-terminally truncated Aβ species in the pathogenesis of Alzheimer’s disease
Liu, K., Solano, I., Mann, D. M. A., Lemere, C. A., Mercken, M. H., Trojanowski, J. Q., & Lee, V. M. ‐. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0077-5 · Cited by 96
Postnatal Development of the Primate Hippocampal Formation
Lavenex, P., Lavenex, P. B., & Amaral, D. G. (2006) · Developmental Neuroscience · doi:10.1159/000096222 · Cited by 92
Possible Compensatory Events in Adult Down Syndrome Brain Prior to the Development of Alzheimer Disease Neuropathology: Targets for Nonpharmacological Intervention
Head, E., Lott, I. T., Patterson, D. W., Doran, E. W., & Haier, R. J. (2007) · Journal of Alzheimer s Disease · doi:10.3233/jad-2007-11110 · Cited by 91
Morphological and biochemical assessment of DNA damage and apoptosis in Down syndrome and Alzheimer disease, and effect of postmortem tissue archival on TUNEL
Anderson, A. J., Stoltzner, S., Lai, F., Su, J. H., & Nixon, R. A. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00126-3 · Cited by 88
Trisomy 21–induced dysregulation of microglial homeostasis in Alzheimer’s brains is mediated by USP25
Zheng, Q., Li, G., Wang, S., Zhou, Y., Liu, K., Gao, Y., Zhou, Y., Zheng, L., Zhu, L., Deng, Q., et al. (2021) · Science Advances · doi:10.1126/sciadv.abe1340 · Cited by 85
Cognition in Down syndrome: a developmental cognitive neuroscience perspective
Edgin, J. O. (2013) · Wiley Interdisciplinary Reviews Cognitive Science · doi:10.1002/wcs.1221 · Cited by 92
On the cause of mental retardation in Down syndrome: extrapolation from full and segmental trisomy 16 mouse models
Galdzicki, Z., Siarey, R. J., Pearce, R., Stoll, J., & Rapoport, S. I. (2001) · Brain Research Reviews · doi:10.1016/s0926-6410(00)00074-4 · Cited by 84
Prospects for Improving Brain Function in Individuals with Down Syndrome
Costa, A. C. S., & Scott-McKean, J. J. (2013) · CNS Drugs · doi:10.1007/s40263-013-0089-3 · Cited by 83
Amyloid-β and Astrocytes Interplay in Amyloid-β Related Disorders
Batarseh, Y. S., Duong, Q.-V., Mousa, Y. M., Rihani, S. B. A., Elfakhri, K. H., & Kaddoumi, A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030338 · Cited by 82
Single cell gene expression profiling in Alzheimer’s disease
Ginsberg, S. D., Che, S., Counts, S., & Mufson, E. J. (2006) · NeuroRx · doi:10.1016/j.nurx.2006.05.007 · Cited by 76
Bach1 Overexpression in Down Syndrome Correlates with the Alteration of the HO-1/BVR-A System: Insights for Transition to Alzheimer's Disease
Di Domenico, F., Pupo, G., Mancuso, C., Barone, E., Paolini, F., Arena, A., Blarzino, C., Schmitt, F. A., Head, E., Butterfield, D. A., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-141254 · Cited by 75
β2-microglobulin functions as an endogenous NMDAR antagonist to impair synaptic function
Gao, Y., Hong, Y., Huang, L., Zheng, S., Zhang, H., Wang, S., Yao, Y., Zhao, Y., Zhu, L., Xu, Q., et al. (2023) · Cell · doi:10.1016/j.cell.2023.01.021 · Cited by 75
Do Astrocytes Collaborate with Neurons in Spreading the “Infectious” Aβ and Tau Drivers of Alzheimer’s Disease?
Prà, I. D., Chiarini, A., Gui, L., Chakravarthy, B., Pacchiana, R., Gardenal, E., Whitfield, J. F., & Armato, U. (2014) · The Neuroscientist · doi:10.1177/1073858414529828 · Cited by 79
Maternal Choline Supplementation: A Potential Prenatal Treatment for Down Syndrome and Alzheimer's Disease
Strupp, B. J., Powers, B. E., Velázquez, R., Ash, J. A., Kelley, C. M., Alldred, M. J., Strawderman, M. S., Caudill, M. A., Mufson, E. J., & Ginsberg, S. D. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150921100311 · Cited by 72
USP25 inhibition ameliorates Alzheimer’s pathology through the regulation of APP processing and Aβ generation
Zheng, Q., Song, B., Li, G., Cai, F., Wu, M., Zhao, Y., Jiang, L., Guo, T., Shen, M., Hou, H., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci152170 · Cited by 73
Age dependence of brain β-amyloid deposition in Down syndrome
Jennings, D. L., Seibyl, J. P., Sabbagh, M. N., Lai, F., Hopkins, W. E., Bullich, S., Gimenez, M., Reininger, C. B., Pütz, B., Stephens, A. W., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001212 · Cited by 74
Positron Emission Tomography of Brain β-Amyloid and Tau Levels in Adults With Down Syndrome
Nelson, L. D., Siddarth, P., Kepe, V., Scheibel, K. E., Huang, S. C., Barrio, J. R., & Small, G. W. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.104 · Cited by 72
Aging with Down Syndrome—Where Are We Now and Where Are We Going?
Alldred, M. J., Martini, A. C., Patterson, D., Hendrix, J. A., & Granholm, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10204687 · Cited by 72
Volumetric and visual rating of magnetic resonance imaging scans in the diagnosis of amnestic mild cognitive impairment and Alzheimer's disease
Shen, Q., Loewenstein, D., Potter, E., Zhao, W., Appel, J., Greig, M. T., Raj, A., Acevedo, A., Schofield, E., Barker, W., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.07.002 · Cited by 70
The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer's Disease
Iulita, M. F., & Cuello, A. C. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150921100030 · Cited by 69
Zinc-bound metallothioneins as potential biological markers of ageing
Mocchegiani, E., Giacconi, R., Cipriano, C., Muzzioli, M., Fattoretti, P., Bertoni–Freddari, C., Isani, G., Zambenedetti, P., & Zatta, P. F. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00468-3 · Cited by 64
Glutamatergic Transmission Aberration: A Major Cause of Behavioral Deficits in a Murine Model of Down's Syndrome
Kaur, G., Sharma, A., Xu, W., Gerum, S., Alldred, M. J., Subbanna, S., Basavarajappa, B. S., Pawlik, M., Ohno, M., Ginsberg, S. D., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.5338-13.2014 · Cited by 58
Alzheimer's disease therapeutic research: the path forward
Aisen, P. S. S. (2009) · Alzheimer s Research & Therapy · doi:10.1186/alzrt2 · Cited by 59
Cerebrovascular contributions to aging and Alzheimer's disease in Down syndrome
Wilcock, D. M., Schmitt, F. A., & Head, E. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.11.007 · Cited by 56
Cognitive Functioning in Children with Down Syndrome: Current Knowledge and Future Directions
Lukowski, A. F., Milojevich, H. M., & Eales, L. (2019) · Advances in child development and behavior · doi:10.1016/bs.acdb.2019.01.002 · Cited by 56
Neurogenetic disorders across the lifespan: from aberrant development to degeneration
Hickman, R. A., O’Shea, S. A., Mehler, M. F., & Chung, W. K. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-021-00595-5 · Cited by 59
Exploring Alzheimer Molecular Pathology in Down's Syndrome Cerebrospinal Fluid
Portelius, E., Soininen, H. S., Andréasson, U., Zetterberg, H., Persson, R., Karlsson, G., Blennow, K., Herukka, S., & Mattsson, N. (2014) · Neurodegenerative Diseases · doi:10.1159/000358800 · Cited by 51
Positron Emission Tomography and Neuropathologic Estimates of Fibrillar Amyloid-β in a Patient With Down Syndrome and Alzheimer Disease
Sabbagh, M. N. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.535 · Cited by 52
Poor Sleep as a Precursor to Cognitive Decline in Down Syndrome : A Hypothesis
Fernandez, F. (2013) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000124 · Cited by 51
Frontal cortex and striatal cellular and molecular pathobiology in individuals with Down syndrome with and without dementia
Perez, S. E., Miguel, J. C., He, B., Malek‐Ahmadi, M. H., Abrahamson, E. E., Ikonomović, M. D., Lott, I. T., Doran, E. W., Alldred, M. J., Ginsberg, S. D., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01965-6 · Cited by 48
Down syndrome
Rafii, M. S., Kleschevnikov, A. M., Sawa, M., & Mobley, W. C. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804766-8.00017-0 · Cited by 54
Estrogen alters amyloid precursor protein as well as dendritic and cholinergic markers in a mouse model of Down syndrome
Granholm, A., Sanders, L., Seo, H., Lin, L., Ford, K. A., & Ole Isacson, A. (2003) · Hippocampus · doi:10.1002/hipo.10130 · Cited by 50
BACE-2 is overexpressed in Down’s syndrome
Barbiero, L., Benussi, L., Ghidoni, R., Alberici, A., Russo, C., Schettini, G., Pagano, S., Parati, E. A., Mazzoli, F., Nicosia, F. M., et al. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00049-9 · Cited by 49
Development of interlaminar astroglial processes in the cerebral cortex of control and Down’s syndrome human cases.
Colombo, J. A., Reisin, H. D., Jones, M., & Bentham, C. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2004.11.024 · Cited by 48
The effects of assisted cycling therapy (ACT) and voluntary cycling on reaction time and measures of executive function in adolescents with Down syndrome
Ringenbach, S. D. R., Holzapfel, S. D., Mulvey, G. M., Jimenez, A., Benson, A. M., & Richter, M. (2016) · Journal of Intellectual Disability Research · doi:10.1111/jir.12275 · Cited by 48
Down syndrome, beta-amyloid and neuroimaging
Head, E., Helman, A. M., Powell, D. K., & Schmitt, F. A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.09.013 · Cited by 49
Age-dependent oxidative stress-induced DNA damage in Down’s lymphocytes
Zana, M., Szécsényi, A., Czibula, Á., Bjelik, A., Juhász, A., Rimanóczy, Á., Szabó, K., Vetró, Á., Szűcs, P., Várkonyi, Á., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.04.167 · Cited by 45
Neuropathological correlates of amyloid PET imaging in Down syndrome
Abrahamson, E. E., Head, E., Lott, I. T., Handen, B. L., Mufson, E. J., Christian, B. T., Klunk, W. E., & Ikonomović, M. D. (2019) · Developmental Neurobiology · doi:10.1002/dneu.22713 · Cited by 46
A fibril-specific, conformation-dependent antibody recognizes a subset of Aβ plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain
Sarsoza, F. M., Saing, T., Kayed, R., Dahlin, R., Dick, M. B., Broadwater-Hollifield, C., Mobley, S., Lott, I. T., Doran, E. W., Gillen, D. L., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0530-3 · Cited by 44
Alzheimer's Disease and Down Syndrome: From Meiosis to Dementia
Petronis, A. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7128 · Cited by 44
On the Promise of Pharmacotherapies Targeted at Cognitive and Neurodegenerative Components of Down Syndrome
Costa, A. C. S. (2011) · Developmental Neuroscience · doi:10.1159/000330861 · Cited by 44
Serum MHPG Strongly Predicts Conversion to Alzheimer's Disease in Behaviorally Characterized Subjects with Down Syndrome
Dekker, A. D., Coppus, A. M. W., Vermeiren, Y., Aerts, T., van Duijn, C. M., Kremer, B. P. H., Naudé, P., Dam, D. V., & Deyn, P. P. D. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140783 · Cited by 42
Dissecting Alzheimer disease in Down syndrome using mouse models
Choong, X. Y., Tosh, J., Pulford, L. J., & Fisher, E. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00268 · Cited by 41
Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study
Pentz, R., Iulita, M. F., Ducatenzeiler, A., Videla, L., Benejam, B., Carmona‐Iragui, M., Blesa, R., Lleó, A., Fortea, J., & Cuello, A. C. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12229 · Cited by 40
Aberrant Oligodendrogenesis in Down Syndrome: Shift in Gliogenesis?
Reiche, L., Küry, P., & Göttle, P. (2019) · Cells · doi:10.3390/cells8121591 · Cited by 28

Authors: Leverenz, J. B., & Raskind, M. A.
Affiliations: University of Washington (US)
ORCID: Leverenz, James B.
Raskind, Murray A.
Venue: Experimental Neurology
Publisher: Elsevier BV
Published: 1998-04
Volume: 150
Issue: 2
Pages: 296-304
ISSN: 0014-4886 (ISSN-L)
DOI: 10.1006/exnr.1997.6777
OpenAlex: W1994573232
Cited by: 214
References: 33
Citations by year: 2026: 3 · 2025: 9 · 2024: 10 · 2023: 10 · 2022: 9 · 2021: 14 · 2020: 9 · 2019: 11 · 2018: 7 · 2017: 12 · 2016: 4 · 2015: 15 · 2014: 17 · 2013: 7 · 2012: 9
FWCI: 3.07
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Experimental Neurology (publishedVersion)
PubMed (publishedVersion)
Funders: AGE-WELL
Ministerul Cercetării, Inovării şi Digitalizării
National Institute on Aging (AG 05136, AG00503, P50AG005136)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: Down syndrome, amyloid-beta deposition, Alzheimer's disease, medial temporal lobe, hippocampus, parahippocampal gyrus, inferior temporal gyrus, neuritic plaques
MeSH terms: Adolescent, Adult, Age Factors, Aged, Aging, Alzheimer Disease, Child, Child, Preschool, Down Syndrome, Female, Hippocampus, Humans, Immunohistochemistry, Infant, Infant, Newborn, Male, Organ Specificity, Reference Values, Regression Analysis, Temporal Lobe, Amyloid beta-Peptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Early Amyloid Deposition in the Medial Temporal Lobe of Young Down Syndrome Patients: A Regional Quantitative Analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks